ENDRA Life Sciences (NDRA) Competitors $4.14 +0.03 (+0.73%) Closing price 04:00 PM EasternExtended Trading$4.14 0.00 (0.00%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock NDRA vs. NXL, TNON, MHUA, XAIR, LYRA, DHAI, OSRH, INBS, CODX, and LUCYShould you be buying ENDRA Life Sciences stock or one of its competitors? The main competitors of ENDRA Life Sciences include Nexalin Technology (NXL), Tenon Medical (TNON), Meihua International Medical Technologies (MHUA), Beyond Air (XAIR), Lyra Therapeutics (LYRA), DIH Holding US (DHAI), OSR (OSRH), Intelligent Bio Solutions (INBS), Co-Diagnostics (CODX), and Innovative Eyewear (LUCY). These companies are all part of the "medical equipment" industry. ENDRA Life Sciences vs. Its Competitors Nexalin Technology Tenon Medical Meihua International Medical Technologies Beyond Air Lyra Therapeutics DIH Holding US OSR Intelligent Bio Solutions Co-Diagnostics Innovative Eyewear ENDRA Life Sciences (NASDAQ:NDRA) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Do analysts recommend NDRA or NXL? ENDRA Life Sciences presently has a consensus target price of $50.00, indicating a potential upside of 1,107.73%. Nexalin Technology has a consensus target price of $5.00, indicating a potential upside of 444.78%. Given ENDRA Life Sciences' higher possible upside, analysts clearly believe ENDRA Life Sciences is more favorable than Nexalin Technology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ENDRA Life Sciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Nexalin Technology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is NDRA or NXL more profitable? ENDRA Life Sciences has a net margin of 0.00% compared to Nexalin Technology's net margin of -5,057.14%. ENDRA Life Sciences' return on equity of -194.14% beat Nexalin Technology's return on equity.Company Net Margins Return on Equity Return on Assets ENDRA Life SciencesN/A -194.14% -127.89% Nexalin Technology -5,057.14%-209.20%-186.87% Which has better earnings and valuation, NDRA or NXL? Nexalin Technology has higher revenue and earnings than ENDRA Life Sciences. Nexalin Technology is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioENDRA Life SciencesN/AN/A-$11.51M-$33.89-0.12Nexalin Technology$170K94.05-$7.61M-$0.76-1.21 Which has more volatility & risk, NDRA or NXL? ENDRA Life Sciences has a beta of -0.18, indicating that its share price is 118% less volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 3.69, indicating that its share price is 269% more volatile than the S&P 500. Does the media favor NDRA or NXL? In the previous week, Nexalin Technology had 3 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 4 mentions for Nexalin Technology and 1 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 1.88 beat Nexalin Technology's score of 1.03 indicating that ENDRA Life Sciences is being referred to more favorably in the media. Company Overall Sentiment ENDRA Life Sciences Very Positive Nexalin Technology Positive Do insiders and institutionals have more ownership in NDRA or NXL? 1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are owned by institutional investors. 0.0% of ENDRA Life Sciences shares are owned by company insiders. Comparatively, 25.3% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryENDRA Life Sciences beats Nexalin Technology on 7 of the 13 factors compared between the two stocks. Get ENDRA Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NDRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NDRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NDRA vs. The Competition Export to ExcelMetricENDRA Life SciencesMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.09M$7.06B$5.78B$9.80BDividend YieldN/A1.19%3.95%4.01%P/E Ratio-0.1218.7422.5622.49Price / SalesN/A72.26463.84113.07Price / CashN/A21.6337.7359.36Price / Book2.117.1410.046.68Net Income-$11.51M$176.42M$3.27B$265.59M7 Day Performance-8.81%3.69%3.17%3.42%1 Month Performance-34.80%-1.34%4.34%1.09%1 Year Performance-71.11%10.18%44.12%23.84% ENDRA Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NDRAENDRA Life Sciences2.9237 of 5 stars$4.14+0.7%$50.00+1,107.7%-76.9%$3.09MN/A-0.1220Positive NewsNXLNexalin Technology3.0357 of 5 stars$0.80+2.6%$5.00+521.4%-12.6%$13.66M$170K-1.063Positive NewsTNONTenon Medical2.1082 of 5 stars$1.42+2.2%$5.50+287.3%+138.7%$12.34M$3.28M-0.058MHUAMeihua International Medical Technologies0.8288 of 5 stars$0.40+4.1%N/A-62.3%$12.23M$96.90M0.00620XAIRBeyond Air3.8695 of 5 stars$2.40+3.4%$11.00+358.3%-73.6%$12.12M$3.70M-0.2070LYRALyra Therapeutics3.166 of 5 stars$7.31+3.7%$100.00+1,268.0%-57.4%$11.59M$1.53M-0.2550DHAIDIH Holding US0.9392 of 5 stars$0.30+26.1%N/A-88.1%$11.33M$64.47M-1.01N/APositive NewsHigh Trading VolumeOSRHOSRN/A$0.56+5.8%N/AN/A$10.21MN/A0.00N/APositive NewsGap DownINBSIntelligent Bio Solutions0.3858 of 5 stars$1.50+2.0%N/A+32.5%$10.16M$3.05M-0.7310Positive NewsGap DownCODXCo-Diagnostics4.3217 of 5 stars$0.32+8.8%$5.50+1,618.8%-78.4%$9.88M$3.91M-0.28100LUCYInnovative Eyewear0.6545 of 5 stars$2.02-1.5%N/A-44.9%$9.38M$1.64M-0.739News Coverage Related Companies and Tools Related Companies Nexalin Technology Competitors Tenon Medical Competitors Meihua International Medical Technologies Competitors Beyond Air Competitors Lyra Therapeutics Competitors DIH Holding US Competitors OSR Competitors Intelligent Bio Solutions Competitors Co-Diagnostics Competitors Innovative Eyewear Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NDRA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ENDRA Life Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ENDRA Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access